Clinical Trial

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Study acronym: ADfind
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-25; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT06906497
Lead Sponsor Johann E Gudjonsson MD PhD
Collaborators: Dermira, Inc., Almirall, S.A.
Conditions Atopic Dermatitis
Enrollment 48 participants
Start Date 2025-07-02
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-11